Post-Operative Pain – Pipeline Review, H2 2011

Post-Operative Pain – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Post-Operative Pain - Pipeline Review, H2 2011', provides an overview of the Post-Operative Pain therapeutic pipeline. This report provides information on the therapeutic development for Post-Operative Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Operative Pain. 'Post-Operative Pain - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Post-Operative Pain.
• A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Post-Operative Pain pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Post-Operative Pain therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Post-Operative Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Post-Operative Pain
Post-Operative Pain Therapeutics under Development by Companies
Post-Operative Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Post-Operative Pain Therapeutics – Products under Development by Companies
Post-Operative Pain Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Post-Operative Pain Therapeutics Development
DURECT Corporation
A.P. Pharma, Inc.
Novartis AG
AcelRx Pharmaceuticals, Inc.
Pfizer Inc.
Bayer AG
GW Pharmaceuticals plc
NeurogesX, Inc.
PAION AG
BTG International Ltd
Mundipharma International Limited
McGill University Health Center
SCOLR Pharma, Inc.
Immupharma Plc
Neorphys
Grunenthal GmbH
QRxPharma Limited
Omeros Corporation
Cara Therapeutics, Inc.
Xenome Ltd.
KAI Pharmaceuticals Inc.
Encore Therapeutics Inc.
SantoSolve AS
Endo Pharmaceuticals Inc.
Gaia BioPharma Limited
Qazvin University Of Medical Sciences
Post-Operative Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Celebrex - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
POSIDUR - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ibuprofen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Morphine-6-glucuronide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MoxDuo IR - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
OMS103HP - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Celecoxib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Etoricoxib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Oxycodone hydrochloride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Eutectic Mixture - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pregabalin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ketamine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dexamethasone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lignocaine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
OMS302 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
2PX - DRUG PROFILE
  Product Description
  Mechanism of Action
  R&D Progress
Lidocaine + Bupivacaine + Clonidine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dexmedetomidine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gabapentin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gabapentin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lidocaine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ropivacaine + Sufentanil - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lornoxicam - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pregabalin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pregabalin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ropivacaine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Fentanyl - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Morphine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gabapentin + Morphine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Acetazolamide - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Gabapentine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tramadol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Novafen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Naproxen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Oxymorphone IR - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Bupivacaine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BAY98-7111 + Diphenhydramine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dexmedetomidine + Morphine + Celecoxib - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Botulinum Toxin Type A - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pregabalin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Post-Operative Pain Therapeutics – Drug Profile Updates
Post-Operative Pain Therapeutics – Discontinued Products
Post-Operative Pain – Product Development Milestones
Featured News & Press Releases
Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency
Nov 22, 2011: Cara Therapeutics Initiates Phase I Study With Oral Formulation Of Novel Peripherally-Acting Kappa Opioid Agonist
Nov 08, 2011: QRxPharma Receives Target Date For FDA Action On MoxDuo IR NDA
Oct 28, 2011: Cytogel Pharma Presents Phase I Study Resuls Of Cyt-1010 At American Society of Anesthesiologists
Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302
Oct 04, 2011: InSite Vision Announces Positive Phase II Results For BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
Sep 06, 2011: DURECT Completes Enrollment In Pivotal US Phase III Trial For POSIDUR
Aug 03, 2011: Cara Therapeutics Initiates Phase II Trial Of CR845 In Acute Post-Operative Pain
Jul 18, 2011: QRxPharma Announces NDA Filing For MoxDuo IR
Jun 29, 2011: QRxPharma Announces Additional Data On Phase III Comparative Safety Study Of MoxDuo IR
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Post-Operative Pain, H2 2011
Products under Development for Post-Operative Pain – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
DURECT Corporation, H2 2011
A.P. Pharma, Inc., H2 2011
Novartis AG, H2 2011
AcelRx Pharmaceuticals, Inc., H2 2011
Pfizer Inc., H2 2011
Bayer AG, H2 2011
GW Pharmaceuticals plc, H2 2011
NeurogesX, Inc., H2 2011
PAION AG, H2 2011
BTG International Ltd, H2 2011
Mundipharma International Limited, H2 2011
McGill University Health Center, H2 2011
SCOLR Pharma, Inc., H2 2011
Immupharma Plc, H2 2011
Neorphys, H2 2011
Grunenthal GmbH, H2 2011
QRxPharma Limited, H2 2011
Omeros Corporation, H2 2011
Cara Therapeutics, Inc., H2 2011
Xenome Ltd., H2 2011
KAI Pharmaceuticals Inc., H2 2011
Encore Therapeutics Inc., H2 2011
SantoSolve AS, H2 2011
Endo Pharmaceuticals Inc., H2 2011
Gaia BioPharma Limited, H2 2011
Qazvin University Of Medical Sciences, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Post-Operative Pain Therapeutics – Drug Profile Updates
Post-Operative Pain Therapeutics – Discontinued Products

LIST OF FIGURES

Number of Products under Development for Post-Operative Pain, H2 2011
Products under Development for Post-Operative Pain – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top